Chronic Activation vs Oscillation

QUIET BIOLOGY FRAMEWORK | Scientific Support Document

Finley Proudfoot | Quiet Biology Framework | March 2026

Abstract

Every paper in this series has circled the same underlying problem from a different angle: signalling systems that are designed to switch on and off are being held permanently open. mTOR stays active when it should be resting. AKT stays elevated when insulin has long since cleared. MDM2 stays switched on when there is no active growth signal to warrant it. p53 stays suppressed when the cell has genuine quality-control work to do.

This paper steps back from the individual proteins and asks a more fundamental question: what is the mechanism by which biological signals are supposed to switch, and what happens when that mechanism fails? The answer is phosphorylation, the addition and removal of phosphate groups from proteins, which is the primary language through which cells turn processes on, off, up, down, and sideways. When phosphorylation patterns become fixed rather than rhythmic, the language of the cell breaks down. Signals stop meaning what they are supposed to mean. Regulation fails not because pathways are too strong, but because they have stopped switching.

Phosphorylation is the primary control language, but it operates alongside a parallel acetylation system, regulated by sirtuins, that governs many of the same proteins through the same metabolic conditions. Both languages lose their rhythm under chronic metabolic excess; both are addressed by the same upstream correction. This paper focuses on the phosphorylation mechanism as the foundational layer; the companion Sirtuins/NAD⁺ paper describes the acetylation axis in full.

The quiet biology protocol is, at its most fundamental level, an attempt to restore phosphorylation rhythm, to give each signal the timing, context, and periodicity it needs to carry real biological information.

01The Problem Is Not Magnitude. It Is Persistence.

The conventional approach to diseases like cancer focuses on levels. Too much mTOR activity. Too little p53. Too much androgen receptor signalling. The logical therapeutic response to this framing is to reduce what is too high and increase what is too low, to adjust the dials toward a better set-point.

This framing is not wrong, but it consistently underperforms in practice. Drugs that reduce mTOR activity produce initial responses but then face adaptive resistance. Drugs that aim to activate p53 carry toxicity profiles that limit their use. The pattern suggests that the problem is not simply one of magnitude, and that adjusting levels without restoring dynamics fails to address the actual defect.

The more accurate framing is this: the pathways are not simply elevated. They are chronically active. And chronic activity is a fundamentally different biological state from normal, pulsatile activity, even when the average level looks similar.

In a healthy cell, mTOR rises after a meal and falls during fasting. AKT rises with insulin and returns to baseline as insulin clears. p53 pulses briefly in response to cellular stress, does its inspection work, and returns to its resting state. These are not just quantitative fluctuations. The timing and rhythm of these signals carry information that determines what genes are activated, what cellular processes are prioritised, and what happens next.^[1]

A sustained signal and a pulsatile signal at the same average amplitude are not biologically equivalent. They produce different cellular outcomes.^[2]

The disease state is not simply elevated mTOR or suppressed p53. It is the loss of rhythm in those systems, a transition from pulsatile, context-sensitive signalling to sustained, context-insensitive signalling. Adjusting the level without restoring the rhythm addresses the symptom, not the mechanism.

02Phosphorylation: The Cell’s Primary Control Language

To understand why rhythm matters, it helps to understand how biological signals actually work at the molecular level. The primary mechanism is phosphorylation, the attachment of a phosphate group to a specific location on a protein, carried out by enzymes called kinases, and reversed by enzymes called phosphatases.

Phosphorylation is often described as a simple on/off switch. That description is accurate as far as it goes, but it understates the richness of what phosphorylation actually does. A single phosphorylation event can activate a protein, inhibit a protein, change where in the cell it is located, alter which other proteins it binds to, or determine how quickly it is broken down. Different phosphorylation sites on the same protein can produce opposite effects. The outcome depends not just on whether phosphorylation occurs, but where it occurs, in what sequence, and in what cellular context.^[3]

This makes phosphorylation a multi-directional control system rather than a binary switch. The same protein can be nudged in different directions depending on which kinase acts on it, which phosphatase reverses that action, and what the surrounding signalling environment looks like.

AKT phosphorylating MDM2 produces a different outcome from stress kinases phosphorylating p53, even though both involve phosphate groups being added to proteins in the same general pathway.^[4]

What makes this system work in health is the balance between kinases and phosphatases, between the enzymes that add phosphate groups and those that remove them. Together, they create dynamic, reversible control: signals can be turned on, and they can be turned off again. The cell can respond to a stimulus and then return to its baseline state, ready to respond to the next one. It is this reversibility that allows the cell to distinguish between a brief stress signal and a chronic one, between a normal growth phase and uncontrolled proliferation.

Phosphorylation operates alongside a parallel acetylation system regulated by sirtuins, most critically SIRT1, which deacetylates both p53 and the androgen receptor. Both languages are governed by the same upstream metabolic conditions: NAD⁺ availability for acetylation, AKT tone for phosphorylation. Both degrade under chronic metabolic excess. The MDM2 Convergence paper and the Sirtuins/NAD⁺ paper document both axes in full; this paper focuses on phosphorylation as the primary switching mechanism that sets the biological context in which acetylation operates.

03Oscillation as the Native State of Healthy Biology

Rhythm is not an incidental feature of biological systems. It is a design principle. Virtually every major regulatory pathway in the cell operates through cycles of activation and inactivation, and the timing of those cycles carries biological information that the average level of a signal cannot convey.

The clearest example is p53. Research over the past two decades, most notably from the laboratory of Galit Lahav at Harvard Medical School, has shown that p53 does not simply rise and stay elevated in response to cellular stress. It pulses. In individual cells exposed to DNA damage, p53 rises in a discrete wave, falls back as MDM2 clears it, and then rises again. These pulses occur at a remarkably consistent frequency and amplitude. The number of pulses, not their height, carries the information about how much damage has occurred.^[1]

This pulsatile behaviour is not a quirk of p53. It is a general feature of how cells encode information in signals. The same oscillatory dynamics have been observed in the NF-κB inflammatory pathway, in the ERK growth signalling pathway, and in mTOR activity across the cell cycle. In each case, the rhythm of the signal, how fast it rises, how completely it falls, how long it stays quiet before rising again, determines what genes are activated and what cellular decisions are made. A continuous signal and a pulsatile signal with the same average level produce fundamentally different biological outcomes.^[2][5]

Crucially, mTOR activity has also been shown to oscillate across the cell cycle, peaking during phases of active growth and falling during phases where autophagy and quality control are needed. This oscillation is not driven by rapamycin. It is the natural, healthy state of the system. Rapamycin, used cyclically, does not impose something artificial. It restores a rhythm that chronic metabolic stress has flattened.^[6]

04What Chronic Activation Actually Does

When phosphorylation patterns become fixed rather than rhythmic, three things happen that individually impair cellular function and together create the conditions for disease.

Signal sensitivity is lost

Receptors and signalling proteins that are continuously stimulated become desensitised. The cell stops responding proportionately to the signal because the signal has stopped varying. This is the same principle as noise-induced hearing loss or adaptation to a constant smell: when a stimulus is always present, the system calibrates to it as the new baseline and loses its ability to detect change. A cell in which mTOR is chronically active cannot distinguish between a genuine nutrient surplus and normal metabolic conditions. It has lost the signal.

Feedback loops are overridden

Normal signalling systems contain negative feedback loops that limit their own activity, mechanisms that ensure signals are self-terminating rather than self-sustaining. In the PI3K, AKT, mTOR pathway, active mTOR feeds back to suppress the upstream insulin signalling that activated it, providing a natural brake on the pathway. When this feedback is overwhelmed by chronic insulin signalling, the brake fails. The pathway runs without its natural limit. And without negative feedback, the system loses the precision control that distinguishes a regulated response from runaway activation.^[7]

Biological processes can no longer take turns

Growth, repair, and cellular cleanup are incompatible when run simultaneously. The cell has limited resources, and the same molecular machinery is often shared between competing processes. A cell that is continuously in a growth state has neither the biological resources nor the regulatory capacity to run effective autophagy and quality control at the same time. These processes are supposed to alternate, to take turns. When the growth signal never switches off, cleanup never gets to run. Damage accumulates. The cellular environment degrades. The conditions for disease are progressively established.^[8]

05The Same Mechanism, Opposite Outcomes

One of the more striking features of the phosphorylation system is how context-dependent its outcomes are. The same biochemical mechanism, adding a phosphate group to a protein, can produce opposite biological effects depending on which protein is phosphorylated, which site is modified, and what the surrounding cellular environment looks like.

AKT phosphorylating MDM2 stabilises MDM2, which suppresses p53 and supports AR persistence, the configuration that permits tumour growth. Stress kinases phosphorylating p53 directly stabilise p53, activating its quality-control programme and initiating DNA repair or cell cycle arrest. In both cases, a kinase is adding a phosphate group to a protein. The outcome is diametrically different because the context, which protein, which site, which signalling environment, is different.^[4]

This context-dependence is what makes the phosphorylation system so powerful and so vulnerable. In health, different kinases operate in different cycling windows, growth kinases during the feeding and growth phase, stress kinases during the repair and quality-control phase. The cycling separation means that the same machinery can serve different masters without interference.

In chronic activation, that cycling separation collapses. Growth kinases and stress response kinases operate simultaneously in an environment where neither can fully execute its programme. The cell receives mixed signals and produces confused responses. Regulation degrades.

06Cancer as a State of Stabilised Signalling

The papers in this series have each examined a different aspect of the same underlying problem. Cancer cells depend on stable, continuous mTOR signalling to maintain their anabolic growth programme. They depend on stable AKT activation to keep MDM2 elevated and p53 suppressed. They depend on a stabilised androgen receptor pool to maintain continuous transcriptional output.

What these dependencies share is a requirement for persistence. Tumour growth is not simply driven by the presence of growth signals. It is driven by the reliability of those signals over time.^[9]

A growth signal that appears and then disappears, that rises during the feeding phase and falls during the fasting phase, that activates during the growth window and then yields to quality control, does not provide the stable foundation that sustained tumour proliferation requires.

This is why the quiet biology framework proposes that restoring oscillation is a therapeutic strategy in its own right. A tumour that depends on stable, continuous signalling is a tumour that is vulnerable to the restoration of normal signalling dynamics. Not because the signal is eliminated, but because its persistence is interrupted. The tumour loses the predictability it has been depending on.

Conversely, this is why permanent suppression of individual pathways so often fails clinically. When mTOR is continuously suppressed by a drug, the feedback loops that normally terminate mTOR activity are no longer necessary, and the cell adapts to the suppressed state. The drug has eliminated one source of instability but created another, a new chronic state, in a different configuration, that the tumour can exploit in turn.^[7]

07Quiet Biology: Restoring the Rhythm

The quiet biology protocol does not aim to permanently suppress any pathway, nor to permanently activate any pathway. It aims to restore the rhythm between them. Each element of the protocol contributes to this goal through a different mechanism, and the combined effect is a cellular environment in which phosphorylation patterns can return to something closer to their healthy, oscillatory design.

Cyclic mTOR suppression via rapamycin

Used in a structured on-off pattern, rapamycin does not permanently inhibit mTOR. It creates a period of suppression during which autophagy can run, quality control can proceed, and the feedback systems that chronic activation had overwhelmed can reset. When rapamycin clears and mTOR responsiveness returns, the cell rebuilds in a cleaner environment. The cycle is the intervention. Not the suppression alone.^[8]

Metabolic constraint reducing AKT baseline

Reducing chronic insulin signalling lowers the baseline AKT activity that was keeping MDM2 stabilised and p53 suppressed. This is the most sustained element of the protocol, a continuous background correction of the metabolic environment in which all the other phosphorylation events are occurring. A lower AKT baseline changes the context in which every downstream phosphorylation decision is made. It simultaneously improves NAD⁺ availability, restoring the acetylation control layer that the sirtuin system provides.

Exercise-driven AMPK activation

Exercise activates AMPK, the cell’s energy sensor, which directly opposes mTOR and promotes the catabolic, quality-control-dominant state. More importantly, the stress of exercise produces a brief, controlled activation of p53, a genuine pulse, of the kind that p53 was designed to produce, in response to a real but manageable cellular challenge. This restores the p53, MDM2 feedback oscillation that chronic metabolic suppression had flattened. The cell remembers how to pulse.^[1]

Targeted mitophagy

Urolithin A-driven mitophagy removes damaged mitochondria that were contributing metabolic noise and stress signalling to the cellular environment. A cleaner mitochondrial population produces more consistent metabolic substrates and generates less background ROS, reducing the chronic stress signals that were contributing to the fixed, noisy phosphorylation environment characteristic of metabolic disease. Healthier mitochondria also produce more NAD⁺, supporting the acetylation control layer alongside the phosphorylation restoration.

Structured anabolic phases

The protocol does not eliminate growth. It separates growth from cleanup by allocating them to different cycling phases. The anabolic phase, when mTOR is permitted to rise, protein synthesis resumes, and tissue rebuilding occurs, is a genuine and important part of the cycle. Growth in a cell that has completed a quality-control cycle is growth on a cleaner foundation, with better-regulated phosphorylation patterns, than growth in a cell that has never had the space to clean house.

08The RB Axis, Transcriptional Constraint as a Switching System

The phosphorylation framework described in this paper does not apply only to growth signalling pathways such as AKT and mTOR. It extends to the systems that determine what a cell is allowed to be, the systems that constrain transcriptional accessibility and maintain cellular identity. Chief among these is the RB protein.

RB is conventionally described as a gatekeeper of the cell cycle, preventing progression from G1 to S phase by restraining E2F transcription factors. This description is accurate but incomplete. RB does not simply regulate whether a cell divides. It regulates which transcriptional programmes are accessible at all. It is a constraint system, and that constraint is implemented through phosphorylation.

In its hypophosphorylated state, RB binds E2F and recruits chromatin-modifying complexes that compact DNA and restrict transcriptional access. In this state, the cell is constrained, not only in its ability to divide, but in the range of gene expression programmes it can activate. In its hyperphosphorylated state, RB releases E2F, chromatin becomes more accessible, and transcriptional programmes associated with proliferation and plasticity become available.

This is not a binary switch. It is a dynamic system. RB phosphorylation is normally oscillatory, low during quiescence and early cell cycle phases, rising during growth phases, and falling again as the cell exits proliferation or enters differentiation. The oscillation determines not only whether transcription occurs, but when and in what context. As with mTOR and p53, the meaning of the signal lies in its timing.

When RB phosphorylation oscillates appropriately, transcriptional programmes are activated and silenced in sequence. Differentiation can be maintained, proliferation can occur when required, and the cell can return to a constrained baseline state. The accessible transcriptional landscape is limited, ordered, and context-dependent.

When RB phosphorylation becomes chronically elevated, maintained by persistent CDK activity driven by continuous growth signalling through AKT and mTOR, where the withdrawal of growth signalling that would allow dephosphorylation never arrives, this temporal separation collapses. The cell enters a state of persistent transcriptional permissiveness. Programmes that are normally restricted to specific phases, proliferation, stress adaptation, developmental plasticity, become simultaneously accessible. The constraint is not simply weakened. It is lost as a dynamic system.

This has three consequences that mirror exactly those described for chronic activation of growth pathways:

• Transcriptional specificity is reduced. When chromatin remains persistently accessible, the cell loses the ability to restrict transcription to context-appropriate programmes. Gene expression becomes less selective and more permissive, increasing the likelihood of inappropriate programme activation.
• Cellular identity becomes unstable. Differentiation depends on the exclusion of alternative transcriptional states. When RB-mediated constraint is lost, that exclusion fails. Cells become more plastic, not because new signals have appeared, but because the restriction on what can be expressed has been removed.
• Signal integration becomes unreliable. Transcriptional responses to upstream signals depend on a constrained landscape in which only certain programmes are available. When the landscape is broadly accessible, signals no longer produce specific, predictable outputs. The informational content of the signal is degraded.

The result is not simply increased proliferation. It is expanded possibility. A cell with chronically phosphorylated RB is not just dividing more. It is operating within a broader, less constrained state space. Transcriptional programmes that were previously inaccessible become available. Plasticity increases. Adaptation becomes easier. Resistance emerges not because the cell has acquired new capabilities, but because it has lost the constraints that limited its existing ones.

Restoring oscillation does not simply affect growth signalling. It restores the conditions under which RB can cycle between constrained and permissive states. It allows transcriptional programmes to be activated in sequence rather than simultaneously. It reintroduces the temporal structure that makes specificity possible. RB does not need to be permanently active to maintain control. It needs to be able to switch. When it can no longer do so, the cell does not simply grow. It becomes something else, a system in which the boundaries that define cellular identity have been relaxed, and in which behaviour is determined not by new instructions, but by the absence of constraint.

09Why This Reframes Cancer and Ageing

The loss-of-phosphorylation-rhythm framework has implications that extend beyond any individual pathway or disease. If the fundamental defect in cancer and ageing is the collapse of oscillatory signalling, the transition from pulsatile, context-sensitive phosphorylation to fixed, context-insensitive phosphorylation, then the therapeutic question is not primarily about which pathway to target, but about how to restore the dynamics of the system as a whole.

This reframes cancer progression as something that requires not just the presence of oncogenic signals, but their stability over time. A cancer cell that has strong growth signalling but normal oscillatory dynamics, where that signalling rises and falls on a normal schedule, is a very different proposition from a cancer cell with the same signalling amplitude but chronic, fixed activation. The former is a cell under normal biological control. The latter has escaped that control, not by acquiring new signals, but by losing the cycling regulation of the ones it already has.

It also reframes ageing. The progressive metabolic deterioration associated with ageing, insulin resistance, chronic inflammation, declining mitochondrial quality, accumulated cellular damage, is largely a story of failing oscillation. Fasting periods become less effective at fully suppressing mTOR. Post-meal insulin clearance becomes slower. The kinase, phosphatase balance shifts toward sustained activation. NAD⁺ availability declines, and with it the sirtuin-mediated acetylation control layer that runs alongside the phosphorylation system. The cell loses its ability to complete a full quality-control cycle because the growth signal never fully relents.

In this framing, interventions that restore oscillation, metabolic constraint, structured fasting, cyclic pharmacological intervention, exercise, are not simply healthy lifestyle choices. They are mechanistically targeted at the specific defect that drives both cancer permissiveness and the tissue deterioration of ageing.

10The Unifying Principle

Each paper in this series has examined a specific biological system: mTOR and rapamycin, p53 and MDM2, the androgen receptor, mitophagy and mitochondrial quality, sirtuins and NAD⁺, RB and transcriptional constraint, testosterone and cellular context. In each case, the underlying argument has been the same, expressed through the lens of a different pathway.

The problem is not the signal. The problem is the loss of rhythm in the signal.

mTOR is not pathological. Chronic, fixed mTOR activation is. p53 is not simply protective when maximised. Its pulsatile, context-appropriate activation is what makes it effective. The androgen receptor does not simply drive cancer by being present. A stabilised, persistently active AR pool, one that has lost its normal turnover rhythm, is what creates the permissive environment for progression.^[1]

Phosphorylation is the mechanism through which all of these rhythms are maintained or lost. When kinase activity is persistently dominant over phosphatase activity, when phosphate groups are added faster than they are removed, in a system where insulin, growth factors, and inflammatory signals are always present, the oscillatory design of the cell breaks down. Signals stop carrying information. Feedback loops fail. Processes that should alternate begin to run simultaneously and interfere with each other.

The acetylation system, SIRT1 deacetylating p53 to reset it after each pulse, SIRT1 restraining the AR to limit its transcriptional output, degrades through the same metabolic route. Lower NAD⁺ means lower SIRT1 activity means both regulatory brakes released simultaneously. The two control languages fail together because they are governed by the same upstream conditions.

Quiet biology is, in this sense, a signal rhythm restoration strategy. Not by targeting individual kinases with drugs that permanently shut them down, but by modifying the metabolic and signalling environment in which the kinase, phosphatase balance operates. The goal is to restore the conditions under which the cell’s own oscillatory machinery can function as it was designed to.

There is a distinction here that matters clinically: the difference between signal strength and signal quality. These are not the same thing. A cell in which mTOR is permanently suppressed is not healthy, it is simply stuck in a different fixed state. A cell in which p53 is permanently active is under a different kind of stress from one in which p53 is permanently suppressed, but both represent a loss of the dynamic, context-sensitive regulation that healthy tissue depends on. The goal of the protocol is not to shift the system from one permanent state to another. It is to restore the cell’s ability to move appropriately between states.

When a signal means something only in context, when mTOR activity is meaningful because it rises and falls, when p53 activity is meaningful because it responds to actual cellular need, the cell can regulate itself accurately. When those signals are permanently elevated or permanently suppressed, they lose their informational value. The cell cannot tell the difference between normal and abnormal. Restoring signal quality, the right signal, at the right time, in the right context, is what the protocol is ultimately designed to do. Not maximum cleanup. Not maximum p53 activity. Not minimum mTOR. The right signal, when the biology calls for it.

Conclusion

The papers in this series have built toward a single conclusion from multiple directions. Cancer and metabolic ageing are not primarily diseases of signal magnitude. They are diseases of signal dynamics, of phosphorylation patterns that have become fixed when they were designed to oscillate, and of acetylation patterns that have degraded alongside them through the same upstream metabolic failure.

The therapeutic response to this insight is not to suppress individual pathways more aggressively or to activate protective ones more forcefully. It is to restore the rhythm of the system as a whole, to give growth and repair the cycling separation they need, to allow kinases and phosphatases to complete their cycles, to let p53 pulse and MDM2 reset and mTOR fall and rise again on a schedule that the cell can use to regulate itself.

This is what the quiet biology protocol attempts to do. Not through a single dramatic intervention, but through the combined, sustained modification of the metabolic environment in which phosphorylation dynamics either thrive or degrade. The biology was never broken. The rhythm was lost. And rhythm, unlike a broken gene or a mutated protein, can potentially be restored.

Health is not the absence of signalling.

It is the presence of rhythm.

References

1. 01Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nature Genetics. 2004;36(2):147-150. doi:10.1038/ng1293. Also: Purvis JE, Karhohs KW, Mock C, et al. p53 dynamics control cell fate. Science. 2012;336(6087):1440-1444. doi:10.1126/science.1218351
2. 02Purvis JE, Lahav G. Encoding and decoding cellular information through signaling dynamics. Cell. 2013;152(5):945-956. doi:10.1016/j.cell.2013.02.005. Establishes that the same average signal level produces different cellular outcomes depending on whether the signal is delivered continuously or pulsatilely.
3. 03Hunter T. Signaling, 2000 and beyond. Cell. 2000;100(1):113-127. doi:10.1016/S0092-8674(00)81688-8. Definitive account of phosphorylation as a multi-directional cellular control mechanism.
4. 04Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO Journal. 2002;21(15):4037-4048. doi:10.1093/emboj/cdf406. Also: Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. PNAS. 2001;98(20):11598-11603.
5. 05Albeck JG, Mills GB, Bhatt DL. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. Molecular Cell. 2013;49(2):249-261. doi:10.1016/j.molcel.2012.11.002. Also: Nelson DE, Ihekwaba AE, Elliott M, et al. Oscillations in NF-κB signaling control the dynamics of gene expression. Science. 2004;306(5696):704-708.
6. 06Spencer SL, Cappell SD, Tsai FC, Overton KW, Wang CL, Meyer T. The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell. 2013;155(2):369-383. Also: Fixman ED et al. mTORC1 activity oscillates throughout the cell cycle promoting mitotic entry and differentially influencing autophagy induction. Cell Reports. 2024.
7. 07Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9-22. doi:10.1016/j.ccr.2007.05.008. Also: Carracedo A, Pandolfi PP. The PTEN, PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27(41):5527-5541.
8. 08Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293. doi:10.1016/j.cell.2012.03.017
9. 09Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013